Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive [Seeking Alpha]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Seeking Alpha
AXPAXLI™ leverages proven science and a de-risked trial design, aiming to reduce injection frequency while maintaining vision, targeting a $10B+ market. Phase 1 data and masked SOL-1 observations suggest a high probability of meeting key endpoints, with minimal safety concerns to date. OCUL's $790M cash position ensures funding through 2028, mitigating dilution risk ahead of critical binary catalysts. Colin Anderson Productions pty ltd/DigitalVision via Getty Images Ocular Therapeutix, Inc. ( NASDAQ: OCUL ) is a biopharmaceutical company founded in 2006, focused on developing and commercializing innovative therapies for retinal diseases, glaucoma, and ocular inflammation. Using a proprietary bioresorbable hydrogel-based formulation technology (ELUTYX™), they aim to This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of OCUL either through stock ownership, options, or other derivatives. I wrote this article myself, and it ex
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Ocular Therapeutix: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix GAAP EPS of -$0.29, revenue of $13.25M [Seeking Alpha]Seeking Alpha
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 2/5/26 - Form S-8
- 2/5/26 - Form 10-K
- 2/5/26 - Form 8-K
- OCUL's page on the SEC website